GEM-P chemotherapy is active in the treatment of relapsed Hodgkin lymphoma

Annals of Hematology

Volumn 93, Issue 5, 2014, Pages 827-834

  Hawkes, Eliza A ^a   Barton, Sarah ^a   Cunningham, David ^a   Peckitt, Clare ^a   Chua, Sue ^a   Wotherspoon, Andrew ^a   Horwich, Alan ^a   Potter, Mike ^a   Ethel, Mark ^a   Dearden, Claire ^a   Chau, Ian ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Chemotherapy; Cisplatin; Gemcitabine; Hodgkin lymphoma; Relapsed

Indexed keywords

CISPLATIN; GEMCITABINE; METHYLPREDNISOLONE;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOTRANSPLANTATION; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COHORT ANALYSIS; DEMOGRAPHY; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REFRACTORY PERIOD; RELAPSE; RETROSPECTIVE STUDY; SALVAGE THERAPY; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; NEUTROPENIA; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; THROMBOCYTOPENIA; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 84898925334     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-013-1930-y     Document Type: Article

References (34)

1. Viviani S, Zinzani PL, Rambaldi A et al (2011) ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med 365:203-212
2. Diehl V, Franklin J, Pfreundschuh M et al (2003) Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 348:2386-2395
3. Linch DC, Winfield D, Goldstone AH et al (1993) Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 341:1051-1054
4. Schmitz N, Pfistner B, Sextro M et al (2002) Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 359:2065-2071
5. Goda JS, Massey C, Kuruvilla J et al (2012) Role of salvage radiation therapy for patients with relapsed or refractory Hodgkin lymphoma who failed autologous stem cell transplant. Int J Radiat Oncol Biol Phys 84:e329-e335
6. Sureda A, Canals C, Arranz R et al (2012) Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Espanol de Linfomas/Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 97:310-317
7. Abali H, Urun Y, Oksuzoglu B et al (2008) Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin- dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma. Cancer Investig 26:401-406
8. Chen R, Palmer JM, Thomas SH et al (2012) Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. Blood 119:6379-6381
9. Gopal AK, Ramchandren R, O'Connor OA et al (2012) Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood 120:560-568
10. Younes A, Gopal AK, Smith SE et al (2012) Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol Off J Am Soc Clin Oncol 30:2183-2189
11. Younes A, Sureda A, Ben-Yehuda D et al (2012) Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol Off J Am Soc Clin Oncol 30:2197-2203
12. Peters GJ, Bergman AM, van Haperen VW R et al (1995) Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 22:72-79
13. Aviles A, Neri N, Huerta-Guzman J, Fernandez R (2004) Gemcitabine and cisplatin in refractory malignant lymphoma. Oncology 66:197-200
14. Emmanouilides C, Colovos C, Pinter-Brown L et al (2004) Pilot study of fixed-infusion rate gemcitabine with cisplatin and dexamethasone in patients with relapsed or refractory lymphoma. Clin Lymphoma 5:45-49
15. Chau I, Harries M, Cunningham D et al (2003) Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma. Br J Haematol 120:970-977
16. Ng M, Waters J, Cunningham D et al (2005) Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma. Br J Cancer 92:1352-1357
17. Sirohi B, Cunningham D, Norman A et al (2007) Gemcitabine, cisplatin and methylprednisolone (GEM-P) with or without rituximab in relapsed and refractory patients with diffuse large B cell lymphoma (DLBCL). Hematology 12:149-153
18. Cheson BD, Horning SJ, Coiffier B et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol Off J Am Soc Clin Oncol 17:1244
19. Meignan M, Gallamini A, Haioun C (2009) Report on the First International Workshop on interim-PET-scan in lymphoma. Leuk Lymphoma 50:1257-1260
20. Baetz T, Belch A, Couban S et al (2003) Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol Off J Eur Soc Med Oncol ESMO 14:1762-1767
21. Bartlett NL, Niedzwiecki D, Johnson JL et al (2007) Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol Off J Eur Soc Med Oncol ESMO 18:1071-1079
22. Suyani E, Sucak GT, Aki SZ et al (2011) Gemcitabine and vinorelbine combination is effective in both as a salvage and mobilization regimen in relapsed or refractory Hodgkin lymphoma prior to ASCT. Ann Hematol 90:685-691
23. Josting A, Rudolph C, Mapara M et al (2005) Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann Oncol Off J Eur Soc Med Oncol ESMO 16:116-123
24. Colpo A, Hochberg E, Chen YB (2012) Current status of autologous stem cell transplantation in relapsed and refractory Hodgkin's lymphoma. Oncologist 17:80-90
25. Josting A, Rudolph C, Reiser M et al (2002) Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease. Ann Oncol Off J Eur Soc Med Oncol ESMO 13:1628-1635
26. Sibon D, Ertault M, Al Nawakil C et al (2011) Combined ifosfamide, etoposide and oxalipatin chemotherapy, a low-toxicity regimen for first-relapsed or refractory Hodgkin lymphoma after ABVD/EBVP: a prospective monocentre study on 34 patients. Br J Haematol 153:191-198
27. Ferme C, Mounier N, Divine M et al (2002) Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial. J Clin Oncol Off J Am Soc Clin Oncol 20:467-475
28. Aparicio J, Segura A, Garcera S et al (1999) ESHAP is an active regimen for relapsing Hodgkin's disease. Ann Oncol Off J Eur Soc Med Oncol ESMO 10:593-595
29. Kuruvilla J, Nagy T, Pintilie M et al (2006) Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma. Cancer 106:353-360
30. Villa D, Seshadri T, Puig N et al (2012) Second-line salvage chemotherapy for transplant-eligible patients with Hodgkin's lymphoma resistant to platinum-containing first-line salvage chemotherapy. Haematologica 97:751-757
31. Todd T, Raj S, Camilleri D et al (2009) Intermediate dose gemcitabine-cisplatin combination chemotherapy without treatment delay for cytopenia followed by autografting-a new standard of care in relapsed or refractory Hodgkin lymphoma? Ann Hematol 88:1107-1112
32. Czyz A, Romejko-Jarosinska J, Knopinska-Posluszny W et al. (2012) Treatment strategy based on gemcitabine-containing salvage chemotherapy used with intent to proceed to second stem cell transplant for patients with Hodgkin lymphoma relapsing after a prior autologous transplant. Leuk Lymphoma, 54(5):973-978
33. Smeltzer JP, Cashen AF, Zhang Q et al (2011) Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 17:1646-1652
34. Moskowitz CH, Matasar MJ, Zelenetz AD et al (2012) Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood 119:1665-1670